Legend Biotech's CEO will present company updates at the J.P. Morgan Healthcare Conference on January 14, 2025.
Quiver AI Summary
Legend Biotech Corporation announced that CEO Ying Huang, Ph.D., will present company updates at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, in San Francisco. The presentation is scheduled for 3:45 p.m. PT, and interested parties can access a live audio webcast through the company's Investor Relations webpage, with a replay available 48 hours later. Headquartered in Somerset, New Jersey, Legend Biotech focuses on advanced cell therapies targeting life-threatening diseases and has multiple research and development sites worldwide.
Potential Positives
- Announcement of a presentation at the prestigious J.P. Morgan Healthcare Conference highlights the company's visibility and credibility within the healthcare sector.
- The live audio webcast allows for wider investor engagement, showcasing the company's commitment to transparency and communication.
- Discussion of updates by the CEO indicates potential major developments and ongoing innovation in the company's cell therapy products.
Potential Negatives
- None
FAQ
When will Legend Biotech present at the J.P. Morgan Healthcare Conference?
Legend Biotech will present on January 14, 2025, at 3:45 p.m. PT.
How can I access the Legend Biotech presentation?
You can access the live audio webcast through the Investor Relations section of Legend's website.
Will there be a replay of the presentation?
Yes, a replay of the webcast will be available approximately 48 hours after the presentation.
What does Legend Biotech specialize in?
Legend Biotech specializes in developing advanced cell therapies for life-threatening diseases.
Where is Legend Biotech headquartered?
Legend Biotech is headquartered in Somerset, New Jersey.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LEGN Hedge Fund Activity
We have seen 109 institutional investors add shares of $LEGN stock to their portfolio, and 116 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS removed 2,385,960 shares (-100.0%) from their portfolio in Q2 2024
- INVESCO LTD. added 2,264,560 shares (+9826.3%) to their portfolio in Q3 2024
- BLACKROCK, INC. removed 1,226,198 shares (-21.4%) from their portfolio in Q3 2024
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,203,308 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 1,088,305 shares (-65.6%) from their portfolio in Q3 2024
- WELLINGTON MANAGEMENT GROUP LLP removed 772,998 shares (-27.5%) from their portfolio in Q3 2024
- HOLOCENE ADVISORS, LP removed 761,626 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT.
Investors and other interested parties can access the live audio webcast through the Investor Relations section of Legend’s website. The webcast replay will be available approximately 48 hours after the webcast.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at https://legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn .
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
/Broadcom%20Inc%20HQ%20photo-by%20Sundry%20Photogrpahy%20via%20iStock.jpg)
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
